ProShare Advisors
PRTK

ProShare Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

ProShare Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,375
Closed -$43K – 2217
2022
Q1 		$43K Sell
14,375
-3,383
-19% -$12.7K ﹤0.01% 2124
2021
Q4 		$80K Buy
17,758
+1,234
+7% +$5.85K ﹤0.01% 2231
2021
Q3 		$80K Sell
16,524
-3,784
-19% -$20.9K ﹤0.01% 1937
2021
Q2 		$139K Buy
20,308
+2,337
+13% +$18.9K ﹤0.01% 2232
2021
Q1 		$127K Buy
17,971
+1,264
+8% +$9.1K ﹤0.01% 2136
2020
Q4 		$105K Buy
+16,707
New +$98.3K ﹤0.01% 1982
2019
Q4 		– Sell
-12,454
Closed -$54K – 1809
2019
Q3 		$54K Sell
12,454
-416
-3% -$1.66K ﹤0.01% 1595
2019
Q2 		$51K Sell
12,870
-1,547
-11% -$7.36K ﹤0.01% 1572
2019
Q1 		$77K Buy
14,417
+205
+1% +$1.32K ﹤0.01% 1592
2018
Q4 		$73K Sell
14,212
-2,579
-15% -$19.6K ﹤0.01% 1506
2018
Q3 		$163K Sell
16,791
-633
-4% -$6.38K ﹤0.01% 1626
2018
Q2 		$178K Sell
17,424
-433
-2% -$4.9K ﹤0.01% 1634
2018
Q1 		$232K Sell
17,857
-732
-4% -$10.9K ﹤0.01% 1463
2017
Q4 		$333K Buy
18,589
+1,315
+8% +$27.4K ﹤0.01% 1330
2017
Q3 		$434K Buy
17,274
+1,083
+7% +$25.2K ﹤0.01% 1015
2017
Q2 		$390K Buy
16,191
+2,005
+14% +$44.3K ﹤0.01% 1043
2017
Q1 		$273K Sell
14,186
-3,705
-21% -$58.4K ﹤0.01% 1285
2016
Q4 		$276K Buy
+17,891
New +$232K ﹤0.01% 1426

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

ProShare Advisors's PRTK Position: Q2 2022 in Review

ProShare Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 14,375 shares — an estimated $43K sold.

ProShare Advisors first reported a position in PRTK in Q4 2016 and held it in 18 quarters. The position peaked at $434K in Q3 2017. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

  • ProShare Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 14,375 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $43K.
  • ProShare Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 18 quarters.
  • ProShare Advisors's Paratek Pharmaceuticals, Inc. position peaked at $434K in Q3 2017.
  • 84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.